Adalimumab is a safe option for psoriasis patients with concomitant hepatitis B or C infection: a multicentre cohort study of 37 patients and review of the literature

Journal of the European Academy of Dermatology and Venereology

Volumn 31, Issue 11, 2017, Pages 1853-1859

  Piaserico, S ^a   Dapavo, P ^b   Conti, A ^c   Gisondi, P ^d   Russo, F P ^a  

^a UNIVERSITY OF PADOVA   (Italy)

^b UNIVERSITY OF TURIN   (Italy)

^c UNIVERSITY OF MODENA AND REGGIO EMILIA   (Italy)

^d UNIVERSITY OF VERONA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ADALIMUMAB; ALANINE AMINOTRANSFERASE; ASPARTATE AMINOTRANSFERASE; ANTIINFLAMMATORY AGENT;

ADULT; AGED; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; CLINICAL ARTICLE; COHORT ANALYSIS; CONCURRENT INFECTION; DRUG SAFETY; ECHOGRAPHY; FEMALE; FOLLOW UP; HEALTH CENTER; HEPATITIS B; HEPATITIS C; HUMAN; LIVER FIBROSIS; LONG TERM CARE; MALE; MIDDLE AGED; MULTICENTER STUDY; PATIENT REFERRAL; PRIORITY JOURNAL; PSORIASIS; RETROSPECTIVE STUDY; SCORING SYSTEM; TREATMENT RESPONSE; VIRUS LOAD; VIRUS REACTIVATION; ADOLESCENT; CHILD; CLINICAL TRIAL; COMPLICATION; ITALY; LIVER FUNCTION TEST; PATHOPHYSIOLOGY; VIROLOGY; YOUNG ADULT;

ADALIMUMAB; ADOLESCENT; ADULT; AGED; ANTI-INFLAMMATORY AGENTS; CHILD; FEMALE; HEPATITIS B; HEPATITIS C; HUMANS; ITALY; LIVER FUNCTION TESTS; MALE; MIDDLE AGED; PSORIASIS; VIRAL LOAD; YOUNG ADULT;

EID: 85013420715     PISSN: 09269959     EISSN: 14683083     Source Type: Journal    
DOI: 10.1111/jdv.14146     Document Type: Article

References (26)

1. Pompili M, Biolato M, Miele L, Grieco A. Tumor necrosis factor-α inhibitors and chronic hepatitis C: a comprehensive literature review. World J Gastroenterol 2013; 19: 7867–7873.
2. Abramson A, Menter A, Perrillo R. Psoriasis, hepatitis B, and the tumor necrosis factor-alpha inhibitory agents: a review and recommendations for management. J Am Acad Dermatol 2012; 67: 1349–1361.
3. Carroll MB, Forgione MA. Use of tumor necrosis factor alpha inhibitors in hepatitis B surface antigen-positive patients: a literature review and potential mechanisms of action. Clin Rheumatol 2010; 29: 1021–1029.
4. De Nard F, Todoerti M, Grosso V et al. Risk of hepatitis B virus reactivation in rheumatoid arthritis patients undergoing biologic treatment: Extending perspective from old to newer drugs. World J Hepatol 2015; 7: 344–361.
5. Fotiadou C, Lazaridou E, Ioannides D. Safety of anti-tumor necrosis factor-a agents in psoriasis patients who were chronic hepatitis B carriers: a retrospective report of seven patients and brief review of the literature. J Eur Acad Dermatol Venereol 2011; 25: 471–474.
6. Cho YT, Chen CH, Chiu HY, Tsai TF. Use of anti-tumor necrosis factor-a therapy in hepatitis B virus carriers with psoriasis or psoriatic arthritis: a case series in Taiwan. J Dermatol 2011; 39: 269–273.
7. Conde-Taboada A, Munoz JP, Munoz LC, Lopez-Bran E. Infliximab treatment for severe psoriasis in a patient with active hepatitis B virus infection. J Am Acad Dermatol 2009; 60: 1077–1080.
8. Kaiser T, Moessner J, Patel K, McHutchison JG, Tillmann HL. Life threatening liver disease during treatment with monoclonal antibodies. BMJ 2009; 338: b508.
9. Nosotti L, Francesconi F, Izzi S, Berardesca E, Morrone A, Bonifati C. Safety of antitumor necrosis factor-alpha therapy in psoriatic patients with hepatitis B virus infection. Br J Dermatol 2010; 162: 1408–1410.
10. Kouba M, Rudolph SE, Hrdlicka P, Zuber MA. Hepatitis-B reactivation during treatment with tumor necrosis factor-a blocker adalimumab in a patient with psoriasis arthritis [in German]. Dtsch Med Wochenschr 2012; 137: 23–26.
11. Navarro R, Vilarrasa E, Herranz P et al. Safety and effectiveness of ustekinumab and antitumour necrosis factor therapy in patients with psoriasis and chronic viral hepatitis B or C: a retrospective, multicentre study in a clinical setting. Br J Dermatol 2013; 168: 609–616.
12. Motaparthi K, Stanisic V, Van Voorhees AS, Lebwohl MG, Hsu S, Medical Board of the National Psoriasis Foundation. From the Medical Board of the National Psoriasis Foundation: recommendations for screening for hepatitis B infection prior to initiating anti-tumor necrosis factor-alfa inhibitors or other immunosuppressive agents in patients with psoriasis. J Am Acad Dermatol 2014; 70: 178–186.
13. Lok AS, McMahon BJ. Chronic hepatitis B: update 2009. Hepatology 2009; 50: 661–662.
14. European Association For The Study Of The Liver. EASL clinical practice guidelines: management of chronic hepatitis B virus infection. J Hepatol 2012; 57: 167–185.
15. Lee YH, Bae SC, Song GG. Hepatitis B virus (HBV) reactivation in rheumatic patients with hepatitis core antigen (HBV occult carriers) undergoing anti-tumor necrosis factor therapy. Clin Exp Rheumatol 2013; 31: 118–121.
16. Prignano F, Ricceri F, Pescitelli L et al. Tumour necrosis factor-a antagonists in patients with concurrent psoriasis and hepatitis B or hepatitis C: a retrospective analysis of 17 patients. Br J Dermatol 2011; 164: 645–647.
17. Cassano N, Mastrandrea V, Principi M et al. Anti-tumor necrosis factor treatment in occult hepatitis B virus infection: a retrospective analysis of 62 patients with psoriatic disease. J Biol Regul Homeost Agents 2011; 25: 285–289.
18. Sanz-Bueno J, Vanaclocha F, García-Doval I et al. Risk of reactivation of hepatitis B virus infection in psoriasis patients treated with biologics: a retrospective analysis of 20 cases from the BIOBADADERM database. Actas Dermosifiliogr 2015; 106: 477–482.
19. Navarro R, Concha-Garzón MJ, Castaño C, Casal C, Guiu A, Daudén E. Outcome of patients with serology suggestive of past hepatitis B virus infection during antitumor necrosis factor therapy for psoriasis. Int J Dermatol 2014 Jul; 53: 909–911.
20. Nelson DR, Lim HL, Marousis CG et al. Activation of tumor necrosis factor-alpha system in chronic hepatitis C virus infection. Dig Dis Sci 1997; 42: 2487–2494.
21. Cavazzana I, Ceribelli A, Cattaneo R, Franceschini F. Treatment with etanercept in six patients with chronic hepatitis C infection and systemic autoimmune diseases. Autoimmun Rev 2008; 8: 104–106.
22. Aslanidis S, Vassiliadis T, Pyrpasopoulou A, Douloumpakas I, Zamboulis C. Inhibition of TNF alpha does not induce viral reactivation in patients with chronic hepatitis C infection: two cases. Clin Rheumatol 2007; 26: 261–264.
23. Zein NN. Etanercept as an adjuvant to interferon and ribavirin in treatment-naive patients with chronic hepatitis C virus infection: a phase 2 randomized, double-blind, placebo-controlled study. J Hepatol 2005; 42: 315–322.
24. Richetta AG, Maiani E, Carlomagno V et al. Treatment of erythrodermic psoriasis in HCV+ patient with adalimumab. Dermatol Ther 2009; 22(Suppl 1): S16–S18.
25. Peterson JR, Hsu FC, Simkin PA, Wener MH. Effect of tumour necrosis factor alpha antagonists on serum transaminases and viraemia in patients with rheumatoid arthritis and chronic hepatitis C infection. Ann Rheum Dis 2003; 62: 1078–1082.
26. Di Nuzzo S, Boccaletti V, Fantini C et al. Are anti-TNF-α agents safe for treating psoriasis in hepatitis C virus patients with advanced liver disease? Case reports and review of the literature. Dermatology 2016; 232: 102–106.